Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma von Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K

Volltext

Use of radiation in high risk population with non melanoma skin cancer at a rural cancer center von Prakash, Shikha, Emandi, Sanjay, Prakash, Sucharu

Volltext

Chronic oral administration of CI-994: a Phase 1 study von PRAKASH, Sucharu, FOSTER, Brenda J, MEYER, Mark, WOZNIAK, Antoinette, HEILBRUN, Lance K, FLAHERTY, Lawrence, ZALUPSKI, Mark, RADULOVIC, Louis, VALDIVIESO, Manuel, LORUSSO, Patricia M

Volltext

Innovative biomarker testing initiative in a community oncology setting von Brisbin, Lorraine, Berry, Brittnie, Schuchart, Trey, Ruiz, Frederico, Mirsalehi, Ayda, Dave, Neal, Paulson, R. Steven, Prakash, Sucharu, Prakash, Shikha

Volltext

Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU) von LORUSSO, Patricia M, PRAKASH, Sucharu, WOZNIAK, Antoinette, FLAHERTY, Lawrence, ZALUPSKI, Mark, SHIELDS, Anthony, SANDS, Howard, PARCHMENT, Ralph, JASTI, Bhaskara

Volltext

Chronic Oral Administration of CI-994: A Phase I Study von Prakash, Sucharu, Foster, Brenda J., Meyer, Mark, Wozniak, Antoinette, Heilbrun, Lance K., Flaherty, Lawrence, Zalupski, Mark, Radulovic, Louis, Valdivieso, Manuel, LoRusso, Patricia M.

Volltext